| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
3 |
| Employees |
22 |
| Revenues (TTM) (Millions $) |
18 |
| Net Income (TTM) (Millions $) |
-30 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Sigilon Therapeutics Inc is a biotechnology company that specializes in developing and commercializing cell therapies for chronic and debilitating diseases. The company focuses on creating Shielded Living Therapeutics™, which are therapeutic cells engineered to produce and deliver proteins to treat a wide range of diseases.
Sigilon's proprietary technology enables the encapsulation of therapeutic cells within a biocompatible and immune-privileged matrix, known as Afibromer™. This matrix protects the therapeutic cells from the immune system, allowing for long-term and sustained protein production. By delivering protein-based therapies, Sigilon aims to address the underlying cause of diseases rather than solely managing symptoms.
The company's pipeline includes treatments for hematologic disorders, enzyme deficiencies, endocrine disorders, and more. Sigilon's approach has the potential to revolutionize the treatment options for patients suffering from chronic diseases, offering long-term solutions with reduced side effects and improved efficacy.
Sigilon Therapeutics Inc was founded in 2013 and is headquartered in Cambridge, Massachusetts. The company continues to advance its research and development activities to bring transformative therapies to patients in need.
Company Address: 100 Binney Street, Suite 600 Cambridge 2142 MA
Company Phone Number: 336-7540 Stock Exchange / Ticker: NASDAQ SGTX
|
%
2.51% 